Comparative Pharmacology
Head-to-head clinical analysis: HEXADROL versus PREDNISOLONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXADROL versus PREDNISOLONE ACETATE.
HEXADROL vs PREDNISOLONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
Glucocorticoid receptor agonist; modulates gene expression to inhibit pro-inflammatory cytokines, phospholipase A2, and NF-κB; suppresses immune response and inflammation.
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
5-60 mg orally once daily or divided every 12-24 hours; dose depends on condition and severity. For acute exacerbations, 200-400 mg intramuscularly once.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance.
Terminal elimination half-life: 2-4 hours (plasma); biological (tissue) half-life: 18-36 hours due to prolonged glucocorticoid receptor-mediated effects. Half-life prolonged in hepatic disease.
Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%).
Renal (fraction excreted unchanged: <1%); primarily hepatic metabolism to inactive glucuronide and sulfate conjugates eliminated renally and fecally. After oral administration, 12-15% of dose recovered in bile/feces as metabolites.
Category C
Category D/X
Corticosteroid
Corticosteroid